<DOC>
	<DOCNO>NCT01259505</DOCNO>
	<brief_summary>The purpose study evaluate safety HLA-A*2402 restrict epitope peptide CDCA1，URLC10，KIF20A，DEPDC1 MPHOSPH1 emulsify Montanide ISA 51 .</brief_summary>
	<brief_title>Safety Study Multiple-Vaccine Treat Metastatic Breast Cancer</brief_title>
	<detailed_description>CDCA1，URLC10，KIF20A，DEPDC1 MPHOSPH1 identify cancer specific molecule especially breast cancer use genome-wide expression profile analysis cDNA microarray technique . We determine HLA-A*2402 restrict epitope peptide derive molecule identify peptide significantly induce effective tumor specific CTL response vitro vivo . According finding , trial , evaluate safety , immunological clinical response peptide . Patients vaccinated week patient develop progressive disease unacceptable toxicity . On vaccination day , CDCA1，URLC10，KIF20A，DEPDC1 MPHOSPH1 peptide ( 0.5 , 1 2mg peptide ) mix Montanide ISA 51 administer subcutaneous injection . Repeated cycle vaccine administer patient develop progressive disease unacceptable toxicity , whichever occur first . In phase I study , evaluate safety tolerability peptide vaccine . Also evaluate immunological clinical response vaccine therapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Advanced recurrent breast cancer Resistant anthracyclinebased taxanebased chemotherapy difficult continue chemotherapy due intolerable side effect ( ) Resistant trastuzumab difficult continue due intolerable side effect ( ) her2 positive ECOG performance status 02 Life expectancy &gt; 3 month HLAA*2402 Laboratory value follow 2000/mm3 &lt; WBC &lt; 15000/mm3 Platelet count &gt; 100000/mm3 Bilirubin &lt; 3.0mg/dl Asparate transaminase &lt; 150IU/L Alanine transaminase &lt; 150IU/L Creatinine &lt; 3.0mg/dl Able willing give valid write informed consent Pregnancy ( woman childbearing potential : Refusal inability use effective mean contraception ) Breastfeeding Active uncontrolled infection Concurrent treatment steroid immunosuppressing agent Prior chemotherapy , radiation therapy , immunotherapy within 4 week Decision unsuitableness principal investigator physicianincharge</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>number</keyword>
</DOC>